Executive record

Karen Firestone

Director at Amylyx Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:karen-firestoneVersion: public-0As of: 2026-09-28

Not yet claimed11 published Claims4 sources
  • Director

Key Claims

Biography

Ms. Firestone is Co-founder and Chair Emerita of Aureus Asset Management. She previously spent 22 years at Fidelity Investments managing biotechnology and healthcare funds.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chair Emerita · Organization not publishedAMLX DEF 14A director slate

Claims

Conflicts and accountability

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AMLX DEF 14A director slate

    sec filing · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: Apr 24, 2026
    • Board role: Board role: Director · Claim reviewed: Apr 24, 2026
    • Committee assignments: Committee assignments: Audit, Nominating/Governance · Claim reviewed: Apr 24, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: Apr 24, 2026
    • Executive company: Executive at Aureus Asset Management · Claim reviewed: Apr 24, 2026
    • Executive title: Executive title: Chair Emerita · Claim reviewed: Apr 24, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: Apr 24, 2026

  2. Amylyx Pharmaceuticals, Inc. director board source

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 3, 2026

    Supports 3 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026

  3. Open source

    sec proxy · Source published: Apr 23, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 15, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Amylyx Pharmaceuticals, Inc. · Claim reviewed: May 3, 2026